Currently, patients with advanced prostate cancer generally prefer depot treatments including drugs and surgery to reduce androgen synthesis in the testes, but such treatments do not inhibit androgen production in other parts of the body. Abiraterone, a prostate cancer treatment drug known as Abiraterone, is not yet available for sale in China and was invented by researchers at the Royal Marsden Hospital in southwest London, a world-renowned cancer research and treatment center. It is a drug that inhibits the production of androgens anywhere in the body and shows promise not only by reducing levels of prostate-specific antigen (PSA), which represents tumor activity, but also by helping to shrink tumors, while being indicated for tumor patients who have had chemotherapy in the past. Results from phase III clinical trials have shown that it significantly prolongs the lives of patients with advanced prostate cancer and that the drug has a good safety profile with minimal side effects. Abiraterone is an oral cytochrome oxidase P450 (CYP450)c17 inhibitor that reduces androgen levels by inhibiting CYP450c17, a key enzyme in androgen synthesis, and has an inhibitory effect on androgens in the testes and other parts of the body.